Congress moves to cap drug prices at international levels—pharma stocks tumble

What it does

This bill caps U.S. prescription drug prices at the average price charged in Canada, France, Germany, Italy, Japan, and the United Kingdom. Manufacturers must report their prices annually, and those charging more than the international average face civil penalties equal to 10 times the price difference per unit sold. The goal is to lower drug costs for American patients by tying them to what other wealthy nations pay.

Why we flagged it

The bill's core mechanism is a price cap enforced through international reference pricing—tying U.S. drug prices to a basket of six wealthy nations and penalizing manufacturers who exceed that average. This is a direct regulatory intervention in pharmaceutical pricing, not a subsidy, tax break, or market-neutral measure.

What the text implies

• Manufacturers may respond by raising prices in reference countries (Canada, UK, etc.) to increase the 'average,' effectively shifting the burden to those nations' healthcare systems and potentially triggering retaliatory policy responses.
• The bill does not address biosimilar or generic drug pricing separately, potentially creating unintended incentives around market segmentation or product reformulation to avoid the cap.
• Annual recalculation of the international average creates price volatility and may incentivize manufacturers to time product launches or discontinuations around the calculation cycle.
• The 10x penalty multiplier is severe and may trigger legal challenges on due-process or takings grounds, creating regulatory uncertainty that could delay implementation.
• No explicit carve-out for rare diseases, orphan drugs, or breakthrough therapies—the cap applies uniformly, which may reduce R&D incentives for less profitable but medically important drugs.

Who it affects

Ordinary Americans with prescription drug costs stand to benefit from lower prices. The bill directly addresses a major public complaint—that U.S. drug prices are significantly higher than in other developed nations—and creates a mechanism to reduce out-of-pocket and insurance costs. The primary cost falls on pharmaceutical manufacturers, not the public.

Who stands to gain

• patients and consumers (lower out-of-pocket drug costs)
• health insurers and pharmacy benefit managers (lower claims costs)
• government health programs (Medicare, Medicaid lower drug spending)

Named in the bill

HHS Secretary, Pharmaceutical manufacturers, Canada, France, Germany, Italy, Japan, United Kingdom, FDA, Public Health Service Act, Federal Food, Drug, and Cosmetic Act, Bristol Myers Squibb (BMY) — and 4 more

Where it stands

• May 13, 2025 — Introduced · Congress.gov: “Introduced in House”
• May 13, 2025 — Referred to House Committee on Energy and Commerce · Congress.gov: “Referred to the House Committee on Energy and Commerce”

Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.

Money around this bill

1 lobbying clients named this bill on 2 disclosure filings across 2 quarters, Dec 2025 to Jun 2026. Those filings disclosed $840,000 in lobbying spend. A filing names 10 bills on average, so that figure is what each filing reported, not a share belonging to this bill.

More lobbying clients named this bill than 0% of bills with at least one filing.

Jefferson Van Drew, the sponsor, reported $386,700 in PAC receipts in the 2026 cycle.

• Grifols Shared Services North America Inc — $840,000 on 2 filings

Lobbying Disclosure Act filings through Jul 17, 2026. A filing shows who paid to lobby on a bill it names, not what changed.